Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448286 · ClinicalTrials.gov registry record · Phase 3
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
A Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
- Not yet
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT06448286: Clinical Trial Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT06448286 is a Phase 3 study that has not yet begun recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 60 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06448286, a Phase 3 study, has not yet begun recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and tumor tissue. CEST MRI is a technique that uses differences in the tissue environment, like protein concentration or intracellular pH, to generate contrast differences. CEST MRI may identify tumor tissue that does not enhance with standard of care MRI. PH weighted CEST MRI based surgical resection may be more effective compared to standard of care surgical resection in treating patients with glioblastoma.
Primary Outcome
Multivariate cox and log rank tests will be used to compare progression free survival.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- PROCEDURE Surgical Procedure
- PROCEDURE Contrast-enhanced Magnetic Resonance Imaging
- PROCEDURE Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2031-12-01 |
| Phase | Phase 3 |
What is known before NCT06448286 opens enrollment
NCT06448286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT06448286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06448286 about?
NCT06448286 is a clinical study titled "PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma". This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tu...
What is the current status of trial NCT06448286?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2026-12-01. Estimated completion is 2031-12-01.
What interventions are being tested in trial NCT06448286?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Surgical Procedure (PROCEDURE), Contrast-enhanced Magnetic Resonance Imaging (PROCEDURE), Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06448286?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06448286's enrollment target sits among peer trials
60 1804th of 2000 higher than 177 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI